Bank of America just raised its EUR/USD forecast
Jean Jacques Bienaime, a director at Immunome Inc . (NASDAQ:IMNM), recently acquired 7,800 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The transaction, dated March 25, 2025, was executed at a weighted average price of $7.78 per share, with the price range spanning from $7.37 to $8.51. The purchase comes as the stock trades near its 52-week low of $6.94, having declined 34.56% year-to-date. According to InvestingPro analysis, the stock appears undervalued at current levels. Following this purchase, Bienaime’s total holdings amount to 31,415 shares. The transaction reflects a total investment of approximately $60,684. The company, with a market capitalization of $617 million, maintains a strong liquidity position with a current ratio of 4.08 and more cash than debt on its balance sheet. InvestingPro subscribers can access 15 additional key insights about Immunome’s financial health and market position.
In other recent news, Immunome Inc. has been actively advancing its clinical and financial landscape. The company recently reported its fourth-quarter 2024 earnings, aligning with previous disclosures, and has an estimated $217.3 million in cash, cash equivalents, and marketable securities as of December 31, 2024. Immunome is conducting an underwritten public offering of its common stock, priced at $7.75 per share, with plans to raise approximately $150 million. The offering is managed by investment banks including J.P. Morgan and Guggenheim Securities, and the funds are expected to support ongoing research and development efforts.
Guggenheim Securities recently adjusted its outlook on Immunome by lowering the company’s price target from $35.00 to $25.00, though maintaining a Buy rating. This adjustment reflects the impact of recent financing and the potential success of Immunome’s pipeline, including the Phase I trial for IM-1021 targeting advanced B-cell lymphomas and solid tumors. Immunome has also submitted an Investigational New Drug application for IM-3050, with clinical trials expected to begin in late 2025.
Furthermore, Immunome announced a relocation package for its CFO, Max Rosett, including a $400,000 bonus contingent on his move to Bothell, Washington. This move underscores the company’s commitment to strengthening its executive team. These developments highlight Immunome’s strategic efforts to advance its pipeline and maintain a robust leadership structure in the competitive biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.